D-K6L9

D-K6L9 shows antimicrobial and antibiofilm activities against P. aeruginosa from cystic fibrosis patients. D-K6L9 is stable and resistant to degradation by cystic fibrosis sputum proteases and will not induce bacterial resistance [1].

Product Specifications

CAS Number

[426264-61-1]

UNSPSC

12352209

Target

Bacterial

Type

Peptides

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/d-k6l9.html

Solubility

10 mM in DMSO

Smiles

CC(C)C[C@@H](C(N)=O)NC([C@H](CC(C)C)NC([C@@H](CCCCN)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CCCCN)NC([C@@H](CCCCN)NC([C@@H](CC(C)C)NC([C@H](CC(C)C)NC([C@@H](CCCCN)NC([C@H](CCCCN)NC([C@H](CC(C)C)NC([C@@H](CC(C)C)NC([C@H](CCCCN)NC([C@@H](N)CC(C)C)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O

Molecular Formula

C90H174N22O15

Molecular Weight

1804.48

References & Citations

[1]Ben Hur D, et al. Antimicrobial Peptides against Multidrug-Resistant Pseudomonas aeruginosa Biofilm from Cystic Fibrosis Patients. J Med Chem. 2022;65 (13) :9050-9062.